


IMAGES IN DERMATOLOGY

Disseminated cutaneous T-cell lymphoma: Dermatology in Images

Javier Rosero,^{*,*} Carolina Narváez,^{**} Carmen Santamaría^{***}



A 56-year-old man presents with generalized skin lesions that have evolved over the past 2 years, starting with pruritic erythematous macules that progressed to plaques and tumors. He reports weight loss, occasional night sweats, and intense itching. Examination reveals multiple erythematous-violet nodular lesions, some ulcerated on the back, along with bilateral cervical and axillary lymphadenopathy.

Skin biopsy shows atypical lymphoid infiltration with marked epidermotropism. A CT scan reveals generalized lymphadenopathy. He is diagnosed with stage IVA cutaneous T-cell lymphoma (T3 N3 M0 B2).

This case illustrates the characteristic progression of advanced cutaneous lymphoma. Diagnosis relies on clinical-pathological correlation. Treatment is challenging and generally palliative, including systemic therapies such as interferon and chemotherapy in refractory or advanced cases. Clinical presentation varies, and the course is unpredictable. Emphasis is placed on the importance of a multidisciplinary approach and long-term follow-up to optimize

management, considering the complexity of the disease and its impact on the patient's quality of life.

ORCID: Javier Rosero <https://orcid.org/0000-0002-3635-6653>

¹Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. *F1000Res* [Internet]. 2016 Sep 1 [cited 2023 Jun 25];5 Faculty Rev-1882. Available from: <https://f1000research.com/articles/5-1882/v1> doi: 10.12688/f1000research.8829.1

²Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. *Am J Hematol* [Internet]. 2017 Oct [cited 2023 Jun 25];92(10):1085-1102. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/ajh.24876> doi: 10.1002/ajh.24876

³Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. *J Am Acad Dermatol* [Internet]. 2014 Feb [cited 2023 Jun 25];70(2):205.e1-16. Available from: [https://www.jaad.org/article/S0190-9622\(13\)01087-9/fulltext](https://www.jaad.org/article/S0190-9622(13)01087-9/fulltext) doi: 10.1016/j.jaad.2013.07.049

⁴Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, et al. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017. *Eur J Cancer* [Internet]. 2017 May [cited 2023 Jun 25];77:57-74. Available from: [https://www.ejca.com/article/S0959-8049\(17\)30204-3/fulltext](https://www.ejca.com/article/S0959-8049(17)30204-3/fulltext) doi: 10.1016/j.ejca.2017.02.027

*First-year Dermatology Resident, UTE University Dermatology Service, Novaclínica Santa Cecilia, Quito, Ecuador.

**Dermatologist and Head of Dermatology Service, Novaclínica Santa Cecilia, Quito, Ecuador

Correspondence: javier.rosero94@gmail.com
<https://orcid.org/0000-0002-3635-6653>

How to cite this article: Rosero Caiza JA, Narváez Álvarez CM, Santamaría Burgos C. Disseminated Cutaneous T-Cell Lymphoma: Dermatology in Images. *Rev Dermatol Cent* Úraga. 2025;7(1).

Date of receipt: 15/07/2024

Date of acceptance: 25/11/2024